Intermittent Normoxia Reduces Myocardial Reperfusion Injury (INCPB)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to determine the effect of intermittent normoxic cardiopulmonary bypass (CPB) on inflammatory response, oxidative stress and myocardial reperfusion injury in adult patients undergoing valve replacement. The investigators hypothesized that nuclear factor kappa B (NFkB) was involved in regulating gene expression of myocardial inflammatory factor.
| Condition | Intervention |
|---|---|
|
Hyperoxia |
Procedure: intermittent normoxia |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement |
- plasma concentration of troponin I [ Time Frame: within the first 24h after cardiac surgery ] [ Designated as safety issue: No ]
- gene expression of TNFa, IL-6, and IL-10 in myocardium [ Time Frame: 30 min after aotic de-clamping ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | July 2011 |
| Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Intermittent normoxia
Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
|
Procedure: intermittent normoxia
3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
|
Detailed Description:
Methods:Patients meeting the requirement will be randomized into 2 groups: the control group received hyperoxic reperfusion (PaO2 180-250 mmHg) throughout CPB as routine; the treatment group underwent 3 cycles of 5/5 min normal/high oxygenation (PaO2 80-150/180-250 mmHg) during cardioplegia arrest, and maintained the same hyperoxia as the control group in the rest time of CPB. The clinical data of inotropes requirement, drainage, ventilation and intensive care time will be recorded. Venous blood samples will be taken perioperatively for detecting concentration of troponin I (cTnI), tumor necrosis factor-α , interleukin-6, 10, and malondialdehyde (MDA). Atrial biopsies will be removed before cardioplegia arrest and 30min after aortic de-clamping to determine the extent of neutrophil infiltration (myeloperoxidase activity), NFkB binding DNA activity, and gene expression of inflammatory factors (TNF-α, IL-6, 10).
Statistical analysis:A sample size of at least 32 patients in each group was needed to have a power of 90%, significance at the two-side 5% level, on the basis that a SD of 0.2 ng/ml and a difference in peak serum cTnI release of about 0.15 ng/ml between control and conditioned patients was determined.
Expected Results: The treatment group will have significantly lower release of cTnI, inflammatory factors, and MDA during CPB and afterwards. Intermittent normoxia may be related to less myocardial inflammation characterized by decreased myeloperoxidase activity, gene expression of inflammatory factors, the later may result from reduced activity of NFkB binding to DNA after reperfusion.
Eligibility| Ages Eligible for Study: | 25 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- rheumatic heart valve disease requiring selective aortic or double valve(aortic and mitral valve) replacement
Exclusion Criteria:
- infective endocarditis congenital valve disease previous cardiac surgery complicated with diabetes, coronary artery disease, hypertension or peripheral vascular disease.
receiving aspirin, corticosteroids, angiotensin-converting enzyme inhibitors or statin perioperatively
Contacts and Locations| Contact: Shengxi Chen, M.D. | 86-731-89753413 | shengxi.chen@hotmail.com |
| Contact: Li Li, M.D. | 86-731-84327097 | lovelily0920@yahoo.cn |
| China, Hunan | |
| Department of Cardiothoracic Surgery, Xiangya Hospital, Central South University | Recruiting |
| Changsha City, Hunan, China, 410008 | |
| Contact: Wanjun , Luo 86-731-89753703 luowanjun@yahoo.com | |
| Sub-Investigator: Li Li, M.D. | |
More Information
No publications provided
| Responsible Party: | Shengxi Chen, Department of Cardiothoracic Surgery, Xiangya Hospital, Central South University, China |
| ClinicalTrials.gov Identifier: | NCT01348906 History of Changes |
| Other Study ID Numbers: | INCPB |
| Study First Received: | May 3, 2011 |
| Last Updated: | May 5, 2011 |
| Health Authority: | China: Ministry of Health |
Keywords provided by Central South University:
|
cardiopulmonary bypass |
Additional relevant MeSH terms:
|
Myocardial Reperfusion Injury Reperfusion Injury Hyperoxia Cardiomyopathies Heart Diseases Cardiovascular Diseases |
Myocardial Ischemia Vascular Diseases Postoperative Complications Pathologic Processes Signs and Symptoms, Respiratory Signs and Symptoms |
ClinicalTrials.gov processed this record on May 22, 2013